Pfizer and BioNTech have announced that they are starting the enrollment of Phase 3 pivotal COVID-19 vaccine trial in the country. The study will enroll an estimated 44,000 global participants, which they say will allow a further increase in trial population diversity, and include people with chronic, stable HIV, Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data. What does all of this mean for us and the fight against Covid-19?

Guest: Dr. Bha Ndungane-Tlakul - Pfizer’s Medical Director for South Africa